NCT00658086

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Alnylam Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety,tolerability and antiviral activitity of ALN-RSV01 in RSV infected lung transplant patients

Conditions

• Respiratory Syncytial Virus Infections

Interventions

Type	Name	Description
DRUG	ALN-RSV01	administered by nebulization once daily for 3 days
DRUG	normal saline	administered by nebulization once daily for 3 days

Timeline

• Start date: 2008-04-01
• Primary completion: 2009-04-01
• Completion: 2009-06-01
• First posted: 2008-04-14
• Last updated: 2018-01-29

Locations

13 sites across 2 countries: United States, Australia